Mitsubishi Tanabe Is Making A Huge Mistake: Why We Believe Neuroderm Is A Lemon
Seeking Alpha,
Summary Viceroy believes Mitsubishi Tanabe’s $1.1B acquisition of NeuroDerm will result in a complete write-off.
Summary Viceroy believes Mitsubishi Tanabe’s $1.1B acquisition of NeuroDerm will result in a complete write-off.
Clin Pharmacol. 2014;6:189-94. Epub 2014 Nov 14 Authors: Hinz M, Stein A, Cole T PubMed: 25484598 Submit Comment